Intervention not reported
Overall QoL change score ‐ up to 12 weeks' · people who are undergoing active treatment for cancer
1 finding from 1 review
Intervention not reported
Overall physical function change score ‐ 6 months' · people who are undergoing active treatment for cancer
1 finding from 1 review
Intervention not reported
Overall role function change score ‐ up to 12 weeks' · people who are undergoing active treatment for cancer
1 finding from 1 review
Intervention not reported
Overall role function · people who are undergoing active treatment for cancer
1 finding from 1 review
Intervention not reported
Overall social function change score ‐ up to 12 weeks' · people who are undergoing active treatment for cancer
1 finding from 1 review
Intervention not reported
Overall social function · people who are undergoing active treatment for cancer
1 finding from 1 review
Intervention not reported
Overall QoL · people who are undergoing active treatment for cancer
1 finding from 1 review
Intervention not reported
Overall anxiety · people who are undergoing active treatment for cancer
1 finding from 1 review
Intervention not reported
Overall anxiety · people who are undergoing active treatment for cancer
1 finding from 1 review
Intervention not reported
Overall depression · people who are undergoing active treatment for cancer
1 finding from 1 review
Intervention not reported
Overall depression · people who are undergoing active treatment for cancer
1 finding from 1 review
Intervention not reported
Overall fatigue change score ‐ up to 12 weeks' · people who are undergoing active treatment for cancer
1 finding from 1 review
Intervention not reported
Overall fatigue · people who are undergoing active treatment for cancer
1 finding from 1 review
Intervention not reported
Overall physical function change score ‐ up to 12 weeks' · people who are undergoing active treatment for cancer
1 finding from 1 review
All‐cause mortality (main analysis ‐ active cancer) · patients with cancer with venous thromboembolism
Low molecular weight heparin secondary prophylaxis showed no clear difference in all‐cause mortality (main analysis ‐ active cancer) compared with vitamin K antagonist secondary prophylaxis (low certainty).
1 finding from 1 review
Recurrent venous thromboembolism (main analysis ‐ active cancer) · patients with cancer with venous thromboembolism
Low molecular weight heparin secondary prophylaxis probably leads to lower recurrent venous thromboembolism (main analysis ‐ active cancer) compared with vitamin K antagonist secondary prophylaxis (moderate certainty).
1 finding from 1 review
Major bleeding · patients with cancer with venous thromboembolism
Low molecular weight heparin secondary prophylaxis showed no clear difference in major bleeding (main analysis ‐ active cancer) compared with vitamin K antagonist secondary prophylaxis (low certainty).
1 finding from 1 review
Minor bleeding (main analysis ‐ active cancer) · patients with cancer with venous thromboembolism
It is very uncertain whether low molecular weight heparin secondary prophylaxis changes minor bleeding (main analysis ‐ active cancer) compared with vitamin K antagonist secondary prophylaxis (very low certainty).
1 finding from 1 review
Thrombocytopenia (main analysis‐ active cancer) · patients with cancer with venous thromboembolism
Low molecular weight heparin secondary prophylaxis showed no clear difference in thrombocytopenia (main analysis‐ active cancer) compared with vitamin K antagonist secondary prophylaxis (low certainty).
1 finding from 1 review
Intervention not reported
Post‐immunotherapy treatment response · ovarian carcinoma
1 finding from 1 review